Project Grant R01HL183979
- Federal Project Grant Summary Emory University received a $797,648 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026 through February 28, 2031. This research initiative investigates red blood cell (RBC)-bound cell-free DNA (cfDNA) as a predictor of acute anemia in sickle cell disease (SCD). The project delivers basic and translational scientific research combining clinical sample...
- Federal Project Grant Award Summary The National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded $168,000 to Icahn School of Medicine at Mount Sinai, effective July 1, 2026 through June 30, 2027, to investigate the role of the INTS12 protein in transcription elongation control during human red blood cell development and in Congenital Dyserythropoietic Anemia Type IV (CDA IV), a rare hemolytic anemia affecting children. The project will utilize the newly established BEL-A...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded Boston Children's Hospital $117,525 on July 7, 2025, to investigate cellular adaptation mechanisms in response to one-carbon (1C) metabolism perturbation, with project completion targeted for June 30, 2028. The research will characterize how cells respond to folate depletion by examining the role of ufmylation, a post-translational...
- Federal Project Grant Award Summary Boston Children's Hospital received an $801,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with a completion date of July 31, 2030. This award supports research investigating the role of stress granules in red blood cell development and erythropoiesis, specifically examining...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...
- This Project Grant award, valued at $465,000.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to investigate the mechanisms by which chronic inflammation disrupts the hemostatic balance in sickle cell disease (SCD). Specifically, the project aims to understand how tumor necrosis factor-alpha (TNFa) induced inflammation blocks autophagy and mitophagy in platelets and...
- Federal Grant Award Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a Project Grant totaling $646,383 under the Cardiovascular Diseases Research program (CFDA 93.837). The award was obligated on September 15, 2025, with an ultimate completion date of June 30, 2030. Research Scope and Deliverables: This project investigates red blood cell (RBC) transfusion survival and effectiveness in recipients with sickle cell disease (SCD), a clinical...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Icahn School of Medicine at Mount Sinai $871,028 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a project addressing ineffective erythropoiesis in myelodysplastic syndrome (MDS). The award, effective March 1, 2026, through December 31, 2030, supports basic biomedical research to characterize the mechanisms by which iron...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New Health Sciences, Inc. (doing business as Hemanext Inc.) a Project Grant of $1,017,232 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a rigorous clinical efficacy trial of hypoxic red blood cell (HRBC) transfusions for sickle cell anemia patients. The award, issued on September 5, 2025, with completion targeted for August 31, 2028, will fund the first comparative...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $445,000 project grant effective July 1, 2025, through June 30, 2028, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative will define the mechanisms by which impaired mitochondrial function leads to failure of neutrophil development in patients with severe congenital neutropenia (SCN) caused by CLPB...
FATTY ACID METABOLISM IN NORMAL AND PATHOLOGICAL ERYTHROPOIESIS - PROJECT SUMMARY THE PRODUCTION OF RED BLOOD CELLS (RBC), KNOWN AS 'ERYTHROPOIESIS', SERVES AS A PARADIGM FOR UNDERSTANDING CELLULAR DIFFERENTIATION AND TERMINAL MATURATION. DEFECTS IN ERYTHROPOIESIS OR RBC FUNCTION CAUSE VARIOUS FORMS OF ANEMIA, A HEALTH BURDEN AFFECTING NEARLY ONE-THIRD OF THE GLOBAL POPULATION. EACH STEP OF ERYTHROPOIESIS, INCLUDING LINEAGE SPECIFICATION, PROLIFERATION, DIFFERENTIATION, AND TERMINAL MATURATION INTO RBCS FILLED WITH HEMOGLOBIN FOR OXYGEN TRANSPORT, HAS UNIQUE METABOLIC REQUIREMENTS WITH POTENTIAL OPPORTUNITIES FOR THERAPEUTIC INTERVENTION. FOR INSTANCE, RECENT EVIDENCE INDICATES THAT HEMOGLOBINOPATHIES CAN BE TREATED BY STIMULATING GLYCOLYSIS WITH PYRUVATE KINASE AGONISTS. WE DEMONSTRATED PREVIOUSLY THAT GLUTAMINE SYNTHESIS IS UNIQUELY UPREGULATED DURING ERYTHROPOIESIS TO DETOXIFY AMMONIUM GENERATED BY HEME SYNTHESIS AND THAT ENHANCED GLUTAMINE SYNTHETASE ACTIVITY ALLEVIATES -THALASSEMIA. HOWEVER, THE COMPREHENSIVE METABOLIC REGULATION OF ERYTHROPOIESIS REMAINS POORLY UNDERSTOOD, WHICH LIMITS THERAPEUTIC OPPORTUNITIES. TO ADDRESS THIS KNOWLEDGE GAP, WE PERFORMED GLOBAL METABOLOMIC PROFILING, ISOTOPE TRACING AND TRANSCRIPTOME ANALYSIS OF STAGED ERYTHROID PRECURSORS FROM MOUSE FETAL LIVER AND BONE MARROW. WE DISCOVERED THAT DISTINCT, ONTOGENY-SPECIFIC METABOLIC PROCESSES GOVERN ERYTHROPOIESIS. WHILE GLUCOSE IS THE PRIMARY NUTRIENT FOR BIOENERGETICS AND BIOSYNTHESIS IN FETAL LIVER ERYTHROID PRECURSORS, MITOCHONDRIAL FATTY ACID B-OXIDATION (FAO) BECOMES MORE ACTIVE DURING POSTNATAL BONE MARROW ERYTHROPOIESIS. SURPRISINGLY, ISOTOPE TRACING SHOWED THAT LONG CHAIN FATTY ACIDS ARE ESSENTIAL METABOLIC PRECURSORS FOR TCA CYCLE INTERMEDIATES AND HEME DURING ADULT-TYPE ERYTHROPOIESIS. MOREOVER, GENETIC DISRUPTION OF FAO ENZYMES CAUSED IMPAIRED ERYTHROPOIESIS AND ANEMIA IN ADULT MICE, WHEREAS ERYTHROID FAO WAS PROFOUNDLY DYSREGULATED IN SICKLE CELL DISEASE (SCD). THESE FINDINGS SUPPORT OUR CENTRAL HYPOTHESES THAT FAO PROVIDES ESSENTIAL NUTRIENTS TO SUPPORT ERYTHROPOIETIC ENERGY DEMANDS AND BIOSYNTHETIC NEEDS, INCLUDING HEME BIOSYNTHESIS, AND THAT DYSFUNCTIONAL FAO CONTRIBUTES TO THE PATHOPHYSIOLOGY OF SCD. THUS, THE OBJECTIVE OF THIS PROJECT IS TO ELUCIDATE THE FUNCTIONAL AND MECHANISTIC ROLES OF FATTY ACID METABOLISM AS A NEW REGULATORY PATHWAY IN ERYTHROPOIESIS AND RBC DISORDERS ACCORDING TO THREE SPECIFIC AIMS: 1) DEFINE THE FUNCTIONAL ROLES OF FAO IN ERYTHROPOIESIS; 2) ELUCIDATE THE MECHANISTIC ROLES OF FATTY ACID METABOLISM IN ERYTHROCYTE DEVELOPMENT AND FUNCTION; AND 3) DETERMINE THE ROLE OF FATTY ACID METABOLISM IN THE PATHOPHYSIOLOGY OF SICKLE CELL DISEASE. OUR HYPOTHESES AND THE FEASIBILITY OF PROPOSED STUDIES ARE SUPPORTED BY EXTENSIVE PRELIMINARY DATA COMBINING ORTHOGONAL, STATE-OF-THE-ART METABOLIC AND TRANSCRIPTOMIC APPROACHES WITH ORTHOGONAL MOUSE AND HUMAN MODELS TO ANALYZE ERYTHROPOIESIS IN VIVO. NOW WE WILL ELUCIDATE FATTY ACID METABOLISM AS A CRITICAL METABOLIC REGULATOR OF NORMAL POSTNATAL ERYTHROPOIESIS AND A POTENTIAL THERAPEUTIC TARGET FOR SCD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $835.5k | 6/19/26 |